 NEW YORK--BUSINESS WIRE--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Prevail Therapeutics Inc. NASDAQ: PRVL to Eli Lilly and Company is fair to Prevail shareholders. Under the terms of the merger agreement, Prevail shareholders will receive 22.50 per share in cash plus one non-tradable contingent value right worth up to 4.00 per share in cash. Halper Sadeh encourages Prevail shareholders to click here to learn more about their legal rights and 